<DOC>
	<DOCNO>NCT02966808</DOCNO>
	<brief_summary>Mobility problem multiple sclerosis ( MS ) frequent symptom . It might appear almost 93 % patient first 15 year disease , clear problem normal living . Nevertheless , therapeutic option symptom optimal patient .</brief_summary>
	<brief_title>Retrospective Observational Study About Long-term Effect Fampridine Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The mechanism action fampridine direct effect mobility itÂ´s base voltage-dependent potassium channel function , cause improvement conductivity action-potential neuron . This nowadays approve drug treat walk mobility problem MS . Results obtain Phase III randomize clinical trial prove improvement walk ability measure use Timed 25 Walking Feet test ( T25WF ) . There study regard fampridine effect symptoms different mobility . The ENABLE Phase VI study find first data related long-term impact treatment physical psychological function patient accord perception . Results study indicate , one year treatment , patient perceive sustained benefit health , physical psychologically .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>patient multiple sclerosis fampridine treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>